824 related articles for article (PubMed ID: 31548600)
1. The emerging role of epigenetic therapeutics in immuno-oncology.
Topper MJ; Vaz M; Marrone KA; Brahmer JR; Baylin SB
Nat Rev Clin Oncol; 2020 Feb; 17(2):75-90. PubMed ID: 31548600
[TBL] [Abstract][Full Text] [Related]
2. Cancer Epigenetics, Tumor Immunity, and Immunotherapy.
Cao J; Yan Q
Trends Cancer; 2020 Jul; 6(7):580-592. PubMed ID: 32610068
[TBL] [Abstract][Full Text] [Related]
3. Epigenetics and immunotherapy: The current state of play.
Dunn J; Rao S
Mol Immunol; 2017 Jul; 87():227-239. PubMed ID: 28511092
[TBL] [Abstract][Full Text] [Related]
4. A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy.
Liu Z; Ren Y; Weng S; Xu H; Li L; Han X
Front Immunol; 2022; 13():809761. PubMed ID: 35140720
[TBL] [Abstract][Full Text] [Related]
5. Tackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy.
Lodewijk I; Nunes SP; Henrique R; Jerónimo C; Dueñas M; Paramio JM
Clin Epigenetics; 2021 Mar; 13(1):63. PubMed ID: 33761971
[TBL] [Abstract][Full Text] [Related]
6. Leveraging epigenetics to enhance the efficacy of immunotherapy.
Licht JD; Bennett RL
Clin Epigenetics; 2021 May; 13(1):115. PubMed ID: 34001289
[TBL] [Abstract][Full Text] [Related]
7. Epigenetic Perspective of Immunotherapy for Cancers.
Keshari S; Barrodia P; Singh AK
Cells; 2023 Jan; 12(3):. PubMed ID: 36766706
[TBL] [Abstract][Full Text] [Related]
8. The complex role of EZH2 in the tumor microenvironment: opportunities and challenges for immunotherapy combinations.
Qiu J; Sharma S; Rollins RA; Paul TA
Future Med Chem; 2020 Aug; 12(15):1415-1430. PubMed ID: 32723083
[TBL] [Abstract][Full Text] [Related]
9. Epigenetics in modulating immune functions of stromal and immune cells in the tumor microenvironment.
Pan X; Zheng L
Cell Mol Immunol; 2020 Sep; 17(9):940-953. PubMed ID: 32699350
[TBL] [Abstract][Full Text] [Related]
10. Is there a Role for Epigenetic Enhancement of Immunomodulatory Approaches to Cancer Treatment?
Flower KJ; Ghaem-Maghami S; Brown R
Curr Cancer Drug Targets; 2018; 18(1):5-15. PubMed ID: 28176650
[TBL] [Abstract][Full Text] [Related]
11. Humanized Mice for the Study of Immuno-Oncology.
De La Rochere P; Guil-Luna S; Decaudin D; Azar G; Sidhu SS; Piaggio E
Trends Immunol; 2018 Sep; 39(9):748-763. PubMed ID: 30077656
[TBL] [Abstract][Full Text] [Related]
12. Top 10 Challenges in Cancer Immunotherapy.
Hegde PS; Chen DS
Immunity; 2020 Jan; 52(1):17-35. PubMed ID: 31940268
[TBL] [Abstract][Full Text] [Related]
13. Role of Epigenetic Modifications in Inhibitory Immune Checkpoints in Cancer Development and Progression.
Saleh R; Toor SM; Sasidharan Nair V; Elkord E
Front Immunol; 2020; 11():1469. PubMed ID: 32760400
[TBL] [Abstract][Full Text] [Related]
14. Immuno-oncology and Its Opportunities for Interventional Radiologists: Immune Checkpoint Inhibition and Potential Synergies with Interventional Oncology Procedures.
Hickey RM; Kulik LM; Nimeiri H; Kalyan A; Kircher S; Desai K; Riaz A; Lewandowski RJ; Salem R
J Vasc Interv Radiol; 2017 Nov; 28(11):1487-1494. PubMed ID: 28912090
[TBL] [Abstract][Full Text] [Related]
15. The Cancer Epigenome: Exploiting Its Vulnerabilities for Immunotherapy.
Loo Yau H; Ettayebi I; De Carvalho DD
Trends Cell Biol; 2019 Jan; 29(1):31-43. PubMed ID: 30153961
[TBL] [Abstract][Full Text] [Related]
16. Understanding the epigenetic regulation of tumours and their microenvironments: opportunities and problems for epigenetic therapy.
Liu M; Zhou J; Chen Z; Cheng AS
J Pathol; 2017 Jan; 241(1):10-24. PubMed ID: 27770445
[TBL] [Abstract][Full Text] [Related]
17. Immuno-oncology-101: overview of major concepts and translational perspectives.
Allard B; Aspeslagh S; Garaud S; Dupont FA; Solinas C; Kok M; Routy B; Sotiriou C; Stagg J; Buisseret L
Semin Cancer Biol; 2018 Oct; 52(Pt 2):1-11. PubMed ID: 29428479
[TBL] [Abstract][Full Text] [Related]
18. Immuno-oncology for surgeons.
Lee SL; Al-Shamkhani A; Mirnezami A
Br J Surg; 2019 Sep; 106(10):1273-1282. PubMed ID: 31318438
[TBL] [Abstract][Full Text] [Related]
19. Epigenetics behind tumor immunology: a mini review.
Musella M; Manduca N; Maccafeo E; Sistigu A
Oncogene; 2023 Sep; 42(39):2932-2938. PubMed ID: 37604925
[TBL] [Abstract][Full Text] [Related]
20. Epigenetic Modifiers: Anti-Neoplastic Drugs With Immunomodulating Potential.
Maes K; Mondino A; Lasarte JJ; Agirre X; Vanderkerken K; Prosper F; Breckpot K
Front Immunol; 2021; 12():652160. PubMed ID: 33859645
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
